Topical SGX302 for Mild-to-Moderate Psoriasis

Inclusion Criteria:

• Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable totopical treatment and opaque coverage after application.

• Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).

• Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects withscalp psoriasis included in the treatment area, the total treatment area on body andscalp must not exceed 30%.

Exclusion Criteria:

• Use of topical anti psoriatic therapy within one week prior to the beginning of thestudy and willing to not use other psoriasis treatments for 4 weeks followingcompletion of the treatment portion of the study.

• Received systemic biologic therapy to treat psoriasis within 12 weeks prior to thebeginning of the study.

• Received systemic psoriasis therapy within 4 weeks prior to the beginning of thestudy.

• Received phototherapy (including laser) or photodynamic (light activated drug)therapy within 4 weeks prior to the beginning of the study.